Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  IQVIA Holdings Inc.    IQV


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

IQVIA : Joins UK Government Collaboration to Provide Single Research Platform to Speed Development of New COVID-19 Treatments

share with twitter share with LinkedIn share with facebook
share via e-mail
04/29/2020 | 09:21am EDT

IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, has joined the ACCORD-2 collaboration, which will fast-track development of new treatments for COVID-19. IQVIA will provide a single research platform across the United Kingdom to facilitate multiple clinical trials regardless of sponsor. This strategic alliance will examine the effectiveness of repurposed medicines, potential new drugs, and unlicensed therapies for treating COVID-19 patients.

ACCORD-2 (ACcelerating COVID-19 Research & Development) brings together the National Institute for Health Research (NIHR), 10 of its Biomedical Research Centres led by Southampton Biomedical Research Centre, UK Research and Innovation (UKRI) and industry partners. The ACCORD-2 initiative has received regulatory approval and will immediately begin enrollment of COVID-19 patients into trials to allow urgent access to potential treatments.

The ACCORD-2 collaboration’s accelerated approval process will ensure that patients in significant need receive potentially groundbreaking treatment as trial compounds are delivered to the National Health Service in the coming days and weeks.

The typical study design phase usually takes up to 18 months, but due to the collaborative nature of this agreement among NIHR, UKRI and IQVIA’s partner hospitals, human trials could be possible in several weeks with a goal of compressing that timeline even further.

Drug compounds that demonstrate effectiveness and safety in the early clinical trials stage will then be moved rapidly onto large-scale research platforms, such as the Randomised Evaluation of COVID Therapy (RECOVERY) trial or other standalone IQVIA studies. BerGenBio will provide the first treatment for the study.

IQVIA will quickly recruit patients for the ACCORD-2 studies and will use a range of proprietary technological solutions wherever feasible to minimize infection risk to researchers and to reduce the administrative burden on hard-pressed hospitals.

Members of the comprehensive ACCORD-2 collaboration will make their data and findings available on an open-source basis to enable global information sharing and encourage further collaboration in near real time.

Speaking about IQVIA’s involvement in the ACCORD-2 Collaboration, U.K. General Manager and Senior Vice President for Northern Europe Tim Sheppard said:

“COVID-19 is the greatest public health challenge that has faced the world in a generation. We at IQVIA are proud to be able to use our technology platform, vast network of clinical trial infrastructure and research experience to work with partners developing treatments that could positively alter the course of this pandemic.

“Together with the NIHR, UKRI and Southampton, IQVIA will provide the necessary clinical research capabilities, scientific expertise, innovative technologies, advanced data analytics and drug assessment resources through our team, which includes thousands of U.K.-based clinicians, PhDs, epidemiologists and statisticians. Through this collaboration, we will explore whether treatments already in the research pipeline for other conditions or new compounds that come forward could be instrumental to saving lives.”

Richard Godfrey, chief executive officer of BerGenBio, said:

“We are delighted to be part of this initiative, which is a groundbreaking partnership between government, academia and industry. We are hopeful that our bemcentinib selective AXL inhibitor can play a significant role in the global effort to find suitable treatment options for patients with COVID-19, which has had such serious implications for so many people, and thereby ease pressures on hospital intensive care units and ultimately treat thousands of patients. We are poised to begin dosing in the coming days and will provide results as soon as is practically possible.”


IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Click here to subscribe to Mobile Alerts for IQVIA.

© Business Wire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on IQVIA HOLDINGS INC.
05/26IQVIA : Joins UK Government Collaboration To Find COVID-19 Treatments
05/21IQVIA : Launches the First Solution to Address the Unique Business and Complianc..
05/20IQVIA : Collaborates with Australian Medical Research Institute on COVID-19 Stud..
04/30IQVIA : Management's Discussion and Analysis of Financial Condition and Results ..
04/29IQVIA : Joins UK Government Collaboration to Provide Single Research Platform to..
04/28IQVIA : 1Q Earnings Snapshot
04/28IQVIA HOLDINGS INC. : Results of Operations and Financial Condition, Financial S..
04/28IQVIA : Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance ..
04/27BRISTOL MYERS SQUIBB : Defendant Seeks Rehearing En Banc On Seventh Circuit's De..
04/23IQVIA HOLDINGS INC. : quaterly earnings release
More news
Financials (USD)
Sales 2020 10 727 M - -
Net income 2020 241 M - -
Net Debt 2020 9 570 M - -
P/E ratio 2020 121x
Yield 2020 -
Capitalization 28 553 M 28 553 M -
EV / Sales 2019
EV / Sales 2020 3,55x
Nbr of Employees 67 000
Free-Float 73,2%
Duration : Period :
IQVIA Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 22
Average target price 154,90 $
Last Close Price 149,52 $
Spread / Highest target 17,0%
Spread / Average Target 3,60%
Spread / Lowest Target -17,1%
EPS Revisions
Ari Bousbib Chairman, President & Chief Executive Officer
James Grant Berkshire Senior Vice President-Business Operations
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
John M. Leonard Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP33.49%36 433
MODERNA, INC.214.42%23 913
CELLTRION, INC.25.69%23 085